- Home
- MBOT vs GNLX Comparison
MBOT vs GNLX Comparison
Compare MBOT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | GNLX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9M | 133.0M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MBOT | GNLX |
|---|---|---|
| Price | $1.55 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.50 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 545.7K | 256.0K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,887.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $2.29 |
| 52 Week High | $4.62 | $8.54 |
Technical Indicators
Market Signals| Indicator | MBOT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 46.01 |
| Support Level | N/A | $2.39 |
| Resistance Level | $2.21 | $3.05 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 3.49 | 37.93 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.